15 June 2025 | 1:53PM HKT Potential opportunities on other technology platforms: Referring to technology platform-based collaborations between China pharma / biotech and MNCs (see summary in Exhibit 1), the upfront payment of US$110mn for the announced AZ/CSPC collaboration is consistent with the historical range of US$10mn to below US$200mn, while the total deal size of US$5.3bn was the highest since 2023. With the current collaboration announced to date, we see growing recognition from MNCs for CSPC's tec ...

16 June 2025 | 10:20PM HKT China Healthcare Read across from our global healthcare conference and investor feedback from US marketing We participated in the 46th Global Healthcare Conference (June 9-11) and met with 20+ US investors across Miami and New York. Discussions centered on the momentum behind China biotech's re-rating (+72% YTD, vs +17% for MXCN, see Exhibit 1), driven by a surge in licensing-out deals, particularly in PD-1/VEGF bispecifics, which validated asset quality and innovation. Investors ...